Lithium is the mainstay treatment for bipolar affective disorder, with 0.1 percent of the population being treated. Understanding lithium's complex mechanisms of action will help reveal causes of mood disorders and development of targeted drugs. This project focuses on specific hypotheses concerning lithium's actions, in conjunction with studies of basic neuronal signaling mechanisms. Also, valproate and carbamazepine are therapeutic for bipolar disorder, so biochemical actions common to lithium and these two drugs would strengthen the link to their therapeutic effects. The prime actions of these drugs appear to alter signaling activities which impact on neural plasticity, encompassing regulation of signals leading to transcription factor activation and to regulation of the cytoskeleton.
Specific Aim -1 will test the hypotheses that lithium, valproate, and carbamazopine modulate signaling activities associated with the receptor-coupled phosphoinositide signal transduction system, using muscarinic receptor-expressing human neuroblastoma SH-SY5Y cells as a model system. There are three components to this aim. Component I will test the hypotheses that (a) muscarinic stimulation increases protein tyrosine phosphorylation, including Gq/11, and protein complex formation, (b) tyrosine phosphorylation is necessary for phosphoinositide signaling and activation of AP-1 and Egr-l, (c) these processes are modulated by anti-bipolar drugs. comDonent 2 will test the hypotheses that (a) muscarinic stimulation increases Gq/11 pahnitoylation, (b) pahnitoylation is necessary for optimal signaling, (c) palmitoylation and tyrosine phosphorylation of Gq/11 regulate one another, (d) palmitoylation is modulated by the therapeutic drugs. Component 3 will test the hypotheses that (a) muscarinic stimulation of signaling is modulated by RGS2 (Regulators of G-protein Signaling), (b) association of RGS2 with Gq/11 is regulated by specific mechanisms, (c) RGS2's action is modulated by the therapeutic drugs.
Specific Aim 2 will test the hypotheses that lithium causes alterations in neuronal cytoskeletal organization and function through inhibition of glycogen synthase kinase-3p (GSK3~) resulting in decreased tau and MAP-1B phosphorylation and increased ,B-catenin and Tcf/Lef DNA binding in SH-SY5Y cells. There are three components to this aim.Component I will test the hypotheses that (a) lithium site-specifically reduces phosphorylation of tau and MAP-1B, (b) this is evident at therapeutic lithium concentrations, (c) valproate and carbamazepine affect phosphorylation, (d) these drugs alter localization of tau and MAP-1B, (e) and microtubule stability. Component 2 will test the hypotheses that (a) lithium increases p-catenin levels, (b) this increases cadherin binding (mediates cell adhesion), (c) lithium increases p-catenin-dependent Tcf/Lef transcription factor activation, (d) valproate and carbamazepine have similar effects. Component 3 will test the hypotheses that (a) in postmortem human bipolar brain, tau and MAP-1B have increased site-specific phosphorylation and other alterations opposite those in lithium-treated cells, (b) overexpressed GSK3p in SH-SY5Y cells will model the bipolar condition and will demonstrate enhanced effects of lower concentrations of lithiurn.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
3R01MH038752-19S1
Application #
6641854
Study Section
Special Emphasis Panel (ZRG1 (01))
Program Officer
Brady, Linda S
Project Start
1984-02-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
19
Fiscal Year
2002
Total Cost
$40,486
Indirect Cost
Name
University of Alabama Birmingham
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Grieco, Steven F; Cheng, Yuyan; Eldar-Finkelman, Hagit et al. (2017) Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. Prog Neuropsychopharmacol Biol Psychiatry 72:49-54
Jope, Richard S; Cheng, Yuyan; Lowell, Jeffrey A et al. (2017) Stressed and Inflamed, Can GSK3 Be Blamed? Trends Biochem Sci 42:180-192
Grieco, Steven F; Velmeshev, Dmitry; Magistri, Marco et al. (2017) Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. World J Biol Psychiatry 18:445-456
Pardo, Marta; Beurel, Eleonore; Jope, Richard S (2017) Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome. Eur J Neurosci 45:490-498
Cheng, Yuyan; Pardo, Marta; Armini, Rubia de Souza et al. (2016) Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav Immun 53:207-222
Pardo, M; Abrial, E; Jope, R S et al. (2016) GSK3? isoform-selective regulation of depression, memory and hippocampal cell proliferation. Genes Brain Behav 15:348-55
Beurel, Eléonore; Grieco, Steven F; Amadei, Celeste et al. (2016) Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of ?-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling. Bipolar Disord 18:473-480
Cheng, Yuyan; Jope, Richard S; Beurel, Eleonore (2015) A pre-conditioning stress accelerates increases in mouse plasma inflammatory cytokines induced by stress. BMC Neurosci 16:31
Pardo, Marta; King, Margaret K; Perez-Costas, Emma et al. (2015) Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. Front Behav Neurosci 9:55
Beurel, Eleonore; Grieco, Steven F; Jope, Richard S (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148:114-31

Showing the most recent 10 out of 163 publications